Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
- Conditions
- Myelodysplastic SyndromesLeukemia
- Registration Number
- NCT00899327
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Brief Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients at risk of developing myelodysplastic syndrome may help doctors learn more about changes that occur in DNA and identify biomarkers related to disorders of the blood and bone marrow.
PURPOSE: This research study is looking at biomarkers in patients at risk of developing myelodysplastic syndrome or other disorders and in healthy participants.
- Detailed Description
OBJECTIVES:
Primary
* To identify novel biomarkers of disease that would help in the initial diagnosis of myelodysplastic syndromes (MDS).
Secondary
* To understand the genesis of anemia in cancers.
* To identify novel biomarkers of disease that predict progression of MDS to acute myeloid leukemia.
OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is extracted for molecular analyses, including gene mutation analysis, gene methylation assays, chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of novel biomarkers of disease
- Secondary Outcome Measures
Name Time Method Identification of novel biomarkers of disease progression from myelodysplastic syndromes to acute myeloid leukemia Comprehension of genesis of anemia in cancer
Trial Locations
- Locations (1)
Oxford Radcliffe Hospital
🇬🇧Oxford, England, United Kingdom